<DOC>
<DOCNO>EP-0642497</DOCNO> 
<TEXT>
<INVENTION-TITLE>
NOVEL N-HYDROXYALKYL-SUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE AND PIPERIDINE DERIVATIVES.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3144	A61K3144	A61K31445	A61K31445	A61K31451	A61K31451	A61P900	A61P900	A61P908	A61P910	A61P2500	A61P2528	C07D21100	C07D21114	C07D21118	C07D21122	C07D21152	C07D21170	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61P	A61P	A61P	A61P	A61P	C07D	C07D	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61P9	A61P9	A61P9	A61P9	A61P25	A61P25	C07D211	C07D211	C07D211	C07D211	C07D211	C07D211	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to novel N-hydroxy-substituted 1,2,3,6-tetrahydropyridine and piperidine derivatives of formula (I) wherein A stands for hydrogen or halogen; alkoxy; cyano; phenyl; phenyl monosubstituted by halogen; benzyl; benzyl monosubstituted by halogen; 2-phenylethyl monosubstituted by halogen on the phenyl moiety; or 2-picolyl group; B represents hydrogen; alkoxy or nitro group; D represents hydrogen or halogen; or alkoxy group; or B and D together stand for a -CH=CH-CH=CH- group; R represents hydrogen; alkyl or phenyl group; G is hydrogen; I stands for hydrogen or hydroxy group; or G and I together represent a single chemical bond; E stands for hydrogen or halogen; alkoxy or trifluoromethyl group; and m is 0, 1 or 2, with the proviso that: m is 0 or 2, or both G and I mean hydrogen, when A stands for benzyl or halogen-monosubstituted benzyl group; and m is 1, when A stands for 2-picolyl group, as well as their acid addition salts. The invention further relates to pharmaceutical compositions containing these compounds as active ingredients as well as to a process for the preparation of compounds of formula (I) and their intermediates. The compounds of formula (I) are useful for enhancing the tolerance of mammals (including man) against hypoxic and/or ischaemic states as well as for treating the degenerative and functional disturbances arising from hypoxic and/or ischaemic insults.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
RICHTER GEDEON VEGYESZET
</APPLICANT-NAME>
<APPLICANT-NAME>
RICHTER GEDEON VEGYESZETI GYAR R.T.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
AGAI-CSONGOR EVA
</INVENTOR-NAME>
<INVENTOR-NAME>
BOD PETER
</INVENTOR-NAME>
<INVENTOR-NAME>
BODO MIHALY
</INVENTOR-NAME>
<INVENTOR-NAME>
CSEHI ATTILA
</INVENTOR-NAME>
<INVENTOR-NAME>
CSIZER EVA
</INVENTOR-NAME>
<INVENTOR-NAME>
CSOMOR KATALIN
</INVENTOR-NAME>
<INVENTOR-NAME>
GERE ANIK
</INVENTOR-NAME>
<INVENTOR-NAME>
GIZUR TIBOR
</INVENTOR-NAME>
<INVENTOR-NAME>
HARSANYI KALMAN
</INVENTOR-NAME>
<INVENTOR-NAME>
HEGEDUES BELA
</INVENTOR-NAME>
<INVENTOR-NAME>
KALLAY-SOHONYAI ANNA
</INVENTOR-NAME>
<INVENTOR-NAME>
KAPOLNAS-PAP MARTA
</INVENTOR-NAME>
<INVENTOR-NAME>
KARPATI EGON
</INVENTOR-NAME>
<INVENTOR-NAME>
KISS BELA
</INVENTOR-NAME>
<INVENTOR-NAME>
LAPIS ERZSEBET
</INVENTOR-NAME>
<INVENTOR-NAME>
LASZY JUDIT
</INVENTOR-NAME>
<INVENTOR-NAME>
PALOSI EVA
</INVENTOR-NAME>
<INVENTOR-NAME>
SARKADI ADAM
</INVENTOR-NAME>
<INVENTOR-NAME>
SZABO SANDOR
</INVENTOR-NAME>
<INVENTOR-NAME>
SZENTIRMAI ZSOLT
</INVENTOR-NAME>
<INVENTOR-NAME>
SZOMBATHELYI ZSOLT
</INVENTOR-NAME>
<INVENTOR-NAME>
SZPORNY LASZL
</INVENTOR-NAME>
<INVENTOR-NAME>
AGAI-CSONGOR, EVA
</INVENTOR-NAME>
<INVENTOR-NAME>
BOD, PETER
</INVENTOR-NAME>
<INVENTOR-NAME>
BODO, MIHALY
</INVENTOR-NAME>
<INVENTOR-NAME>
CSEHI, ATTILA
</INVENTOR-NAME>
<INVENTOR-NAME>
CSIZER, EVA
</INVENTOR-NAME>
<INVENTOR-NAME>
CSOMOR, KATALIN
</INVENTOR-NAME>
<INVENTOR-NAME>
GERE, ANIK
</INVENTOR-NAME>
<INVENTOR-NAME>
GIZUR, TIBOR
</INVENTOR-NAME>
<INVENTOR-NAME>
HARSANYI, KALMAN
</INVENTOR-NAME>
<INVENTOR-NAME>
HEGEDUES, BELA
</INVENTOR-NAME>
<INVENTOR-NAME>
KALLAY-SOHONYAI, ANNA
</INVENTOR-NAME>
<INVENTOR-NAME>
KAPOLNAS-PAP, MARTA
</INVENTOR-NAME>
<INVENTOR-NAME>
KARPATI, EGON
</INVENTOR-NAME>
<INVENTOR-NAME>
KISS, BELA
</INVENTOR-NAME>
<INVENTOR-NAME>
LAPIS, ERZSEBET
</INVENTOR-NAME>
<INVENTOR-NAME>
LASZY, JUDIT
</INVENTOR-NAME>
<INVENTOR-NAME>
PALOSI, EVA
</INVENTOR-NAME>
<INVENTOR-NAME>
SARKADI, ADAM
</INVENTOR-NAME>
<INVENTOR-NAME>
SZABO, SANDOR
</INVENTOR-NAME>
<INVENTOR-NAME>
SZENTIRMAI, ZSOLT
</INVENTOR-NAME>
<INVENTOR-NAME>
SZOMBATHELYI, ZSOLT
</INVENTOR-NAME>
<INVENTOR-NAME>
SZPORNY, LASZL
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
 NOVEL N-HYDROXYALKYL-SUBSTITUTED 1,2,3, 6-TETRAHYDRO¬ PYRIDINE AND PIPERIDINE DERIVATIVESThe invention relates to novel N-hydroxyalkyl substi tuted 1,2,3,6-tetrahydropyridine and piperidine deriva¬ tives, to processes and intermediates for their prepara¬ tion, to pharmaceutical compostions containing them and to their medical use.International Patent Application PCT/HU90/00076 describes tetrahydropyridine derivatives structurally related to the compounds of the invention which are said to have antiamnesic activity. In contrast to the present compounds, however, said compounds can be considered as β- or τ-amino ketone compounds the nitrogen atom of whic is closed as a ring member into said substituted tetra¬ hydropyridine ring.The invention relates to novel, therapeutically acti N-hydroxyalkyl-substituted 1,2, 3, 6-tetrahydropyridine an piperidine derivatives of the formulawhereinA stands for hydrogen or halogen; alkoxy; cyano; phenyl; phenyl monosubstituted by halogen; benzyl; benzyl monosubstituted by halogen; 2-phenylethyl monosubstituted by halogen on the phenyl moiety; or 2-picolyl group;76080-67 SI 

 B represents hydrogen; alkoxy or nitro group; D represents hydrogen or halogen; or alkoxy grou or B and D together stand for a -CH=CH-CH=CH- group; R represents hydrogen; alkyl or phenyl group; G is hydrogen;I stands for hydrogen or hydroxy group; or G and I together represent a single chemical bond; E stands for hydrogen or halogen; alkoxy or tri- fluoro ethyl group; and m is 0, 1 or 2, with the proviso that: is 0 or 2, or both G and I mean hydrogen, when stands for benzyl or halogen-monosubstituted benzyl group; and m is 1, when A stands for 2-picolyl group, as well as their acid addition salts.Alkyl group as used herein either in itself or as a moiety of an other group, represents a straight or branched chain saturated hydrocarbon group containing 1-1 carbon atoms such as methyl, ethyl, n- and isopropyl, n-, o-r sec- and tert-butyl groups as well as the various pentyl, hexyl, heptyl, octyl, nonyl and decyl groups. C^_galkyl groups are preferred, C^_ lk l groups are more preferable and methyl group is particularly favour¬ able.Halogen may mean fluorine, chlorine, bromine or iodine. The following compounds are particularly preferred: l-[4-(4-chlorobenzyl)phenyl]-2-(4-phenyl-l,2,3,6-tetra- hydro-1-pyridyl)ethanol,1-[4-(4-chlorobenzyl)phenyl]-3-(4-phenyl-l-piperidyl)- propanol, l-[4-(4-chlorobenzyl)phenyl]-4-(4-phenyl-l,2,3,6-tetra- 


</DESCRIPTION>
<CLAIMS>
C L A I M S
1. A novel N-hydroxyalkyl-substituted 1,2,3,6-tetra¬ hydropyridine and piperidine derivative of the formula
wherein
A stands for hydrogen or halogen; alkoxy; cyano; phenyl; phenyl monosubstituted by halogen; benzyl; benzyl monosubstituted by halogen; 2-phenylethyl monosubstituted by halogen on the phenyl moiety; or 2-picolyl group;
B represents hydrogen; alkoxy or nitro group;
D represents hydrogen or halogen; or alkoxy group; or B and D together stand for a -CH=CH-CH=CH- group; R represents hydrogen; alkyl or phenyl group; G is hydrogen;
I stands for hydrogen or hydroxy group; or G and I together represent a single chemical bond; E stands for hydrogen or halogen; alkoxy or tri- fluoromethyl group; and m is 0, 1 or 2, with the proviso that: m is 0 or 2, or both G and I mean hydrogen, when A stands for benzyl or halogen-monosubstituted benzyl group; and 


 m is 1, when A stands for 2-picolyl group, as well as their acid addition salts.
2. l-[4-(4-chlorobenzyl)phenyl]-2-(4-phenyl-l,2,3,6- tetrahydro-1-pyridyl)ethanol or an acid additions salt thereof as defined in claim 1.
3. 1-[4-(4-chlorobenzyl)phenyl]-3-(4-phenyl-l-piperi propanol or an acid additions salt thereof as defined in claim 1.
4. 1-[4-(4-chlorobenzyl)phenyl]-4-(4-phenyl-l,2,3,6- tetrahydro-1-pyridyl)butanol or an acid additions salt thereof as defined in claim 1.
5. 3-[4-(4-fluorophenyl)-l-piperidyl]-1-(1,1'-bi- phenyl-4-yl)propanol, or an acid additions salt thereof as defined in claim 1. 6. 3-[4-(4-chlorophenyl)-1,2,3,6-tetrahydro-l- pyridyl]
-!-(2,4-dichlorophenyl)propanol or an acid addi¬ tions salt thereof as defined in claim 1.
7. A pharmaceutical composition for treating disorders arising from hypoxia and/or ischaemia, w h i c h c o m p r i s e s as active ingredient a therapeutically effective amount of an N-hydroxyalkyl- substituted 1,2,3,6-tetrahydropyridine or piperidine derivative of the formula (I) , wherein A, B, D, R, G, I, E and m -are as defined in claim 1, or a pharmaceutically acceptable acid addition salt thereof in admixture with one or more carriers and/or additives commonly used in the pharmaceutical industry.
8. A process for the preparation of a novel N- hydroxyalkyl-substituted 1,2,3, 6-tetrahydropyridine or piperidine derivative of formula 

wherein
A stands for hydrogen or halogen; alkoxy; cyano; phenyl; phenyl monosubstituted by halogen; benzyl; benzyl monosubstituted by halogen; 2-phenylethyl monosubstituted by halogen on the phenyl moiety; or 2-picolyl group; B represents hydrogen; alkoxy or nitro group; D represents hydrogen or halogen; or alkoxy group or B and D together stand for a -CH=CH-CH=CH- group; R represents hydrogen; alkyl or phenyl group; G is hydrogen;
I stands for hydrogen or hydroxy group; or G and I together represent a single chemical bond; E stands for hydrogen or halogen; alkoxy or tri- fluoro ethyl group; and m is 0, 1 or 2, with the proviso that: m is 0 or 2, or both G and I mean hydrogen, when stands for benzyl or halogen-monosubstituted benzyl group; and m is 1, when A stands for 2-picolyl group, as well as their acid addition salts w h i c c o m p r i s e s treating an oxo derivative of the formula 

wherein A, B, D, R, G, I, E and m are as defined above, o an acid addition salt thereof with a reducing agent in an organic solvent and then, if desired, converting the obtained N-hydroxyalkyl-substituted 1,2,3,6-tetra¬ hydropyridine or piperidine derivative of formula (I) , wherein A, B, D, R, G, I, E and m are as defined above, t an acid addition salt thereof by reacting it with a mineral or organic acid. 9. The process according to claim 8, w h i c h c o m p r i s e s using a complex metal hydride as reducing agent.
10. The process according to claim 9, w h i c h c o m p r i s e s using sodium borohydride as complex metal hydride.
11. The process according to claim 9, w h i c h c o m p r i s e s using a Cι_
4
alkanol or a mixture of a Cι_4alkanol with water as organic solvent.
12. The process according to claim 8, w h i c h c o m p r i s e s using an aluminum alkoxide in isopropanol medium as reducing agent.
13. A process for the preparation of a pharmaceutical composition, w h i c h c o m p r i s e s mixing as active ingredient a therapeutically effective amount of a novel N-hydroxyalkyl-substituted 1,2,3,6-tetrahydro- 


 pyridine or piperidine derivative of formula (I) , wherein A, B, D, R, G, I, E and m are as defined in claim 1, or pharmaceutically acceptable acid addition salt thereof with one or more carriers and/or additives commonly used in the pharmaceutical industry and formulating the mixture in a pharmaceutical composition.
14. A method for enhancing the tolerance of mammals (including man) against hypoxic and/or ischaemic states a well as for treating the degenerative and functional disturbances arising from hypoxic and/or ischaemic insult w h i c h c o m p r i s e s administering to a subject to be treated a therapeutically effective amount of an N-hydroxyalkyl-substituted 1,2,3,6-tetrahydro¬ pyridine or piperidine derivative of ormula (I) , wherein A, B, D, R, G, I, E-and m are as defined in claim 1, or a pharmaceutically acceptable acid addition salt thereof alone or in the form of a pharmaceutical composition. 15. A compound of formula
wherein
A stands for hydrogen or halogen; alkoxy; cyano; phenyl; phenyl monosubstituted by halogen; benzyl; benzyl monosubstituted by halogen;
2-phenylethyl monosubstituted by halogen on the phenyl moiety; or 2-picolyl group; B represents hydrogen; alkoxy or nitro group; D represents hydrogen or halogen; or alkoxy group-; or 


 B and D together stand for a -CH=CH-CH=CH- group; R represents hydrogen; alkyl or phenyl group; G is hydrogen;
I stands for hydrogen or hydroxy group; or G and I together represent a single chemical bond;
E stands for hydrogen or halogen; alkoxy or tri- fluoromethyl group; and m is 0, 1 or 2, with the proviso that: m is 0 or 2, or both G and I mean hydrogen, when A stands for benzyl or halogen-monosubstituted benzyl group; and m is 1, when A stands for 2-picolyl group, as well as their acid addition salts. 16. A process for the preparation of a novel compound of formula
wherein
A stands for hydrogen or halogen; alkoxy; cyano; phenyl; phenyl monosubstituted by halogen; benzyl; benzyl monosubstituted by halogen; 2-phenylethyl monosubstituted by halogen on the phenyl moiety; or 2-picolyl group;
B represents hydrogen; alkoxy or nitro group;
D represents hydrogen or halogen; or alkoxy group; or B and D together stand for a -CH=CH-CH=CH- group; R represents hydrogen; alkyl or phenyl group; 


 -24-
G is hydrogen;
I stands for hydrogen or hydroxy group; or G and I together represent a single chemical bond; E stands for hydrogen or halogen; alkoxy or tri- fluoromethyl group; and m is 0, 1 or 2, with the proviso that: m is 0 or 2, or both G and I mean hydrogen, when A stands for benzyl or halogen-monosubstituted benzyl group; and is 1, when A stands for 2-picolyl group, as well as their acid addition salts, h i c h c o m p r i s e s a) alkylating a compound of formula
with a halogenated ketone of formula
wherein A, B, D and R are as defined above and X stands for halogen, preferably chlorine or bromine, to obtain compounds of formula (II) , wherein m is 0 or 2; or ) reacting a compound of formula (III) with an acetophe- 


none or propiophenone of formula
wherein A, B, D and R are as defined above and R
1
 means hydrogen or methyl group, in the presence of formal¬ dehyde under conditions of the Mannich's reaction to obtain compounds of formula (II), wherein m is 1. 

</CLAIMS>
</TEXT>
</DOC>
